Heather Jacene, MD (IMAGE)
Caption
"Standard imaging methods, such as CT, MRI, and bone scans, can detect metastases but do not accurately assess how well systemic therapies are working," said Heather Jacene, MD, a nuclear medicine physician from Brigham and Women’s Hospital and Dana-Farber Cancer Institute, who co-led the FEATURE trial for patients with metastatic breast cancer that has advanced primarily, or only, to the bones. "We now have the data to support that with FDG-PET/CT, we can measure the ‘unmeasurable’."
Credit
Brigham and Women’s Hospital
Usage Restrictions
No restrictions.
License
Public Domain